Core Viewpoint - CICC maintains a "outperform" rating for CSPC Pharmaceutical Group (01093) and raises the target price by 9.1% to HKD 12, considering the continued success of external licensing agreements [1] Group 1: Licensing Agreements and Financial Projections - CSPC has signed a research and licensing agreement with AstraZeneca for the exclusive global development, production, and commercialization of 8 innovative long-acting peptide drug projects, excluding mainland China and Hong Kong/Macau [1] - AstraZeneca will pay a total of USD 1.2 billion in upfront payments and up to USD 3.5 billion in cumulative development and sales milestone payments [1] - The company maintains its profit forecasts for 2025 and 2026 at RMB 4.76 billion and RMB 5.35 billion, respectively, and introduces a forecast of RMB 5.70 billion for 2027 [1] Group 2: Market Position and Competitive Landscape - The company is positioned in the long-acting peptide drug market, competing with major players like Pfizer, which acquired Metsera for USD 10 billion to enhance its weight loss drug portfolio [2] - CSPC's SYH2082 is advancing to Phase I clinical trials as a long-acting GLP1R/GIP agonist, with expectations for favorable efficacy and safety data [2] Group 3: Revenue Generation from Licensing - In 2025, the company has already achieved external licensing revenues from various projects, including USD 120 million from oral small molecule GLP-1 and USD 110 million from the AstraZeneca strategic collaboration [3] - The company has a pipeline of innovative assets, including EGFR ADC and SiRNA series, which are expected to lead to further successful licensing agreements and milestone revenue recognition [3]
中金：石药集团(01093)与阿斯利康达成重磅合作 维持“跑赢行业”评级